Wolfe Research

Business

Beyond the Headlines: Three ASX Penny Stocks Drawing Investor Scrutiny Amid Market Volatility

While broader market sentiment remains cautious, a closer look reveals potential in select small-cap opportunities. We examine three ASX-listed penny stocks—Argenica Therapeutics, SenSen Networks, and Vita Life Sciences—that are navigating unique paths in biotech, AI, and healthcare, offering distinct risk-reward profiles for discerning investors.

Feb 5, 2026

Business

MarketAxess Q4 Earnings Preview: Can the Bond Trading Platform Regain Momentum?

All eyes are on MarketAxess Holdings Inc. as the electronic bond trading pioneer prepares to release its fourth-quarter results. With shares under pressure and a mixed backdrop for financial data firms, investors are gauging whether the company can deliver a much-needed beat and provide optimistic guidance for the year ahead.

Feb 5, 2026

Business

Philip Morris International Set to Report Q4 Earnings Amid Shift to Smoke-Free Future

Philip Morris International (NYSE: PM) is scheduled to release its fourth-quarter earnings before market open on Friday, with investors keenly watching the tobacco giant's progress in its smoke-free product transition and financial resilience.

Feb 5, 2026

Business

AutoNation Set to Report Q4 Earnings Amid Flat Revenue Expectations

AutoNation (NYSE: AN) is scheduled to release its fourth-quarter earnings before the market opens on Friday, with analysts projecting steady revenue but closely watching performance in a cooling retail auto market.

Feb 5, 2026

Business

Bitcoin Tumbles Below $72K as Macro Fears, Leverage Unwind Spark Selloff

Bitcoin's sharp decline tests its short-term role as an inflation hedge, with analysts pointing to a broader market deleveraging and macroeconomic uncertainty as key drivers. The sell-off has reignited debates about the cryptocurrency's near-term trajectory.

Feb 5, 2026

Business

Memory Crunch Squeezes Smartphone Giants: Qualcomm, Arm Feel the Pinch as Chip Sales Falter

A persistent industry-wide memory shortage is hampering smartphone production and denting sales forecasts for key chip sector players Qualcomm and Arm Holdings, with executives warning the supply constraints could extend for years.

Feb 5, 2026

Business

Insiders Bet Big on Treasury Wine Estates, Pouring AU$290 Million into Shares

Executives and directors at Treasury Wine Estates have invested over AU$290 million in company stock over the past year, signaling strong internal confidence despite a lower current share price. The buying spree, led by Chairman Olivier C. Goudet, comes as the global wine giant navigates market shifts.

Feb 5, 2026

Business

Valuation Alarm Bells Ring for Apple: A Deep Dive into the Bear Case

As Apple's stock trades near all-time highs, a detailed financial analysis suggests its market price may be significantly disconnected from its intrinsic value, raising questions about sustainability for investors.

Feb 5, 2026

Business

Centene Corporation: A Deep-Value Bet in Healthcare's Defensive Stronghold

Amidst market fears over Medicaid margins and political noise, Centene Corporation (CNC) presents a compelling bull case. Analysts argue its government-backed, counter-cyclical business model and steep discount to intrinsic value signal a multi-year recovery opportunity.

Feb 5, 2026

Business

Alibaba's Cloud Surge Fuels Bullish Turnaround Narrative

Alibaba Group's stronger-than-expected quarterly results, led by a sharp acceleration in its cloud computing division, are reigniting investor optimism and bolstering the case for a sustained recovery in the Chinese tech giant's fortunes.

Feb 5, 2026

Business

Marvell Technology: Market Missteps Create a Value Opportunity in Data Infrastructure

Despite recent stock pressure driven by market speculation, Marvell Technology's solid fundamentals, robust data center growth, and compressed valuation present a compelling case for investors, according to a detailed analysis of the semiconductor firm's outlook.

Feb 5, 2026

Business

Visa's Bull Case: Network Effects and Capital Discipline Fuel Long-Term Growth Thesis

Amid market volatility, a detailed analysis highlights Visa Inc.'s resilient business model, wide economic moat, and shareholder-friendly capital allocation as pillars supporting a compelling long-term investment case, despite recent valuation pressures.

Feb 5, 2026

Business

Celestica's Slide: A Buying Opportunity or a Sign of Fading Momentum?

Celestica's (TSX:CLS) shares have faced significant pressure recently, declining over 7% in a single day and extending losses across multiple timeframes. This pullback, juxtaposed against strong long-term returns, has investors questioning whether the stock's current valuation presents a compelling entry point or reflects deeper concerns about its growth trajectory.

Feb 5, 2026

Business

Upstart Holdings: A High-Stakes Valuation Puzzle Amidst Stock Slide

Upstart Holdings (UPST) faces a critical investor dilemma as its share price languishes near $38, starkly contrasting its high P/E ratio and bullish long-term fair value estimates. We examine whether the market is overlooking a deep value opportunity or correctly pricing in significant execution risks.

Feb 5, 2026

Business

Popular Inc. Sees Fair Value Uptick as Analysts Eye Mid-Cap Bank Recovery

Analysts have revised Popular Inc.'s fair value estimate upward, signaling a shift in sentiment for the mid-cap banking sector as firms look toward 2026 for potential outperformance.

Feb 5, 2026

Business

Denali Therapeutics Gains Momentum Ahead of Key Rare Disease Data Presentations

Denali Therapeutics (DNLI) shares have surged nearly 50% in three months as the biotech firm prepares to unveil new clinical data for its Enzyme Transport Vehicle platform at the upcoming WORLDSymposium. Investors are weighing whether the recent rally has fully priced in the pipeline's potential.

Feb 5, 2026

Business

Altria's Rally: Has the Tobacco Giant's Run Left Value on the Table?

Despite a powerful multi-year surge, a deep dive into Altria Group's valuation suggests its shares may still be trading at a significant discount. We analyze the DCF and P/E metrics behind the numbers and what they mean for investors eyeing the stock after its 120% five-year climb.

Feb 5, 2026

Business

Beyond the Hype: Can Lemonade's AI-Driven Model Finally Deliver Profits?

A detailed analysis of the bullish investment thesis for insurtech disruptor Lemonade, Inc. (LMND), examining its path to profitability, AI-powered scaling, and the significant challenges that remain.

Feb 5, 2026

Business

Crocs Stock: A Contrarian Bet on Comfort and Cash Flow

Despite lingering skepticism over its HEYDUDE acquisition, Crocs, Inc. (CROX) presents a compelling value case. With a rock-bottom valuation, aggressive buybacks, and resilient international growth, the iconic clog maker is betting that its financial discipline can outshine fashion risk.

Feb 5, 2026

Business

Disney's Linear TV Drag: Why the Magic Kingdom Faces a Prolonged Storm

As CEO Bob Iger's tenure nears its end, a growing chorus of analysts warns that Disney's legacy television assets are becoming an unsustainable burden, threatening to overshadow the strength of its parks and studios and potentially leading to prolonged stock underperformance.

Feb 5, 2026